Paul J. Hauptman

TL;DR: Shared decision making for advanced heart failure has become both more challenging and more crucial as duration of disease and treatment options have increased as mentioned in this paper, and the ethical and legal mandate to involve patients in medical decisions has become more and more challenging.

TL;DR: Working with opinion leaders and providing performance feedback can accelerate adoption of some beneficial AMI therapies (eg, aspirin, beta-blockers), andSecular changes in knowledge and hospital protocols may extinguish outdated practices.

TL;DR: Use of lifesaving therapies for eligible patients with AMI is higher than previously reported, particularly for aspirin and thrombolytic use in nonelderly patients and increased adherence to AMI treatment guidelines is required for elderly patients and women.

TL;DR: At the time of hospital discharge, readily available clinical characteristics are associated with HF patients at high risk for persistently unfavorable QoL or death over the next 6 months and can target patients for whom aggressive treatment options and/or end-of-life discussions should be strongly considered.

TL;DR: This article evaluated a guideline-implementation intervention of clinician education by local opinion leaders and performance feedback to increase use of lifesaving drugs (aspirin and thrombolytics in eligible elderly patients, β-blockers in all eligible patients) for acute myocardial infarction (AMI), and decrease the use of potentially harmful therapy (prophylactic lidocaine).